Transforming Allergy Treatment

R & D

Publications List

Cross-reactivity in Grasses: Biochemical Attributes Define Exemplar Relevance.

Bullimore A, Batten T, Hewings S, Fischer von Weikersthal-Drachenberg KJ, Skinner M.
Source.World Allergy Organ J. 2012 Oct;5(10):111-9.

Click here to read the abstract

A battery of genotoxicity studies with an allergy vaccine adjuvanted with monophosphoryl lipid A (MPL®) for the treatment of grass pollen allergy.

Reeve L, Baldrick P, Hewings S, Skinner M. J Appl. Toxicol. 2012; 32: 608-616

Click here to read the abstract

Reproduction and juvenile animal toxicology studies in the rat with a new allergy vaccine adjuvanted with monophosphoryl lipid A (MPL(®)) for the treatment of grass pollen allergy.

Baldrick P, Hewings S, Skinner M. Reprod Toxicol. 32 (2011) 322-328

Click here to read the abstract

A proteomic style approach to characterise a grass mix product reveals potential immunotherapeutic benefit.

Bullimore, AD, Swan, NJ, Alawode, WA, Skinner, MA. WAO Journal 2011
4: 140-146.

Click here to read the abstract

Pollinex Quattro® Ragweed: Safety Evaluation of a New Allergy Vaccine Adjuvanted with Monophosphoryl Lipid A (MPL®) for the Treatment of Ragweed Pollen Allergy

Paul Baldrick, Derek Richardson, Stefan R. Woroniecki* and Beverley Lees
J Applied Toxicology 2007; 27 (4): 399-409

Click here to read the abstract

Modern Approaches to Therapeutic Vaccination as Treatment for Type 1 Respiratory Hypersensitivity (Allergy).

Alan W Wheeler and Stefan R Woroniecki
Expert Rev Vaccines 2006; 5(1): 27-31

Click here to read the abstract

Ultra-short-course seasonal allergy vaccine (Pollinex® Quattro)

Paul L McCormack and Antona J Wagstaff
Drugs 2006; 66(7): 931-938

Click here to read the abstract

Allergy Vaccination receives a positive reaction

Wilkinson K
European Pharmaceutical Contractor, Summer 2006

Click here to read the abstract

Collaboration between Allergy Therapeutics plc and the University of Brighton: development of improved allergy vaccine formulations incorporating Phosphatidyl Serine (PS).

M.J. Dixon, G.J. Phillips, M.A. Skinner, J. Smart and T. Holdich.
Business Innovation for Small-Medium Sized Enterprises. 2006. University of Brighton.

Click here to read the abstract

Phosphatidyl serine (PS) derivatives alter the immune response of Brown Norway rats.

M.J. Dixon, G.J. Phillips, M.A. Skinner, A. Berry and A.W. Wheeler.
Clinical and Experimental Allergy. 2006. 36, 1201.

Click here to read the abstract

Phosphatidyl serine (PS) derivatives alter the immune response of Brown Norway rats.

M.J. Dixon, G.J. Phillips, M.A. Skinner, A. Berry and A.W. Wheeler. Clinical and Experimental Allergy. 2006.
36, 1201.

Click here to read the abstract

Monophosphoryl lipid A (MPL®) promotes allergen-induced immune deviation in favour of Th1 responses

Puggioni F, Durham SR, Francis JN
Allergy 2005; 60(5): 678-684.

Click here to read the abstract

Allergoid-specific T-cell reaction as a measure of the immunological response to specific immunotherapy (SIT) with a Th1-adjuvanted allergy vaccine

V von Baehr, A Hermes, R von Baehr, H-P Scherf, H-D Volk, K J Fischer von Weikersthal-Drachenberg, and SR Woroniecki J
Invest Allergol Clin Immunol 2005; 15(4): 234-241

Click here to read the abstract

Allergy vaccines - new approaches to an old concept

A W Wheeler and S R Woroniecki
Expert Opinion in Biological Therapy 2004; 4(9): 1473-1481

Click here to read the abstract

Safety evaluation of a new allergy vaccine containing the adjuvant monophosphoryl lipid A (MPL®) for the treatment of grass pollen allergy

Paul Baldrick, Derek Richardson, Alan W. Wheeler and Stefan R. Woroniecki
J. Appl. Toxicol 2004; 24: 261-268

Click here to read the abstract

Short-term preseasonal immunotherapy with birch pollen allergoid plus monophosphoryl lipid A (MPL®): influence on cytokine production of peripheral T-cells in patients with allergic rhinitis

Boris A. Stuck, Solange Schneider-Gene, Dirk Schafer, Ludger Klimek and Karl Harmann
Allergy Clin Immunol Int - J World Allergy Org 2004; 16: 60-64.

Click here to read the abstract

Sublingual specific immunotherapy for adults and children: a post-marketing surveillance study

KJ Drachenberg, E Urban, S Proell, SR Woroniecki.
Allergol Immunopathol 2004; 32(2): 76-81

Click here to read the abstract

Allergy vaccines: past, present and future

Woroniecki SR and Wheeler AW
CPD Bulletin Immunology and Allergy 2004; 3(3): 63-67

Click here to read the abstract

Single-course specific immunotherapy with mixed pollen allergoids: results of a multi-centre study

Drachenberg KJ. Proell S, Urban E and Woroniecki SR
Allergologia et Immunopathologia 2003; 31(2): 77-82

Click here to read the abstract

Specific immunotherapy with tyrosine-adsorbed allergens: a post-marketing surveillance study

Drachenberg KJ, Proell S, Woroniecki SR
International Review of Allergology & Clinical Immunology 2003; 9(1): 9-13

Click here to read the abstract

Allergen-specific immunotherapy with a monophosphoryl lipid A-adjuvanted vaccine: reduced seasonally boosted immunoglobulin E production and inhibition of basophil histamine release by therapy-induced

Mothes N, et al
Clin Exp Allergy 2003; 33: 1198-1208

Click here to read the abstract

Efficacy and tolerability of short-term specific immunotherapy with pollen allergoids adjuvanted by monophosphoryl lipid A (MPL®) for children and adolescents

KJ Drachenberg, M Heinzkill, E Urban , SR Woroniecki
Allergol et Immunopathol 2003; 31(5):270-277

Click here to read the abstract

Safety evaluation of a glutaraldehyde modified tyrosine adsorbed housedust mite extract containing monophosphoryl lipid A (MPL®) adjuvant: a new allergy vaccine for dust mite allergy.

Baldrick P, Richardson R, Wheeler AW.
Vaccine 2002; 20: 737-743

Click here to read the abstract

Safety Evaluation of Monophosphoryl Lipid A (MPL® adjuvant): An Immunostimulatory Adjuvant

Baldrick P, Richardson D, Elliott G, Wheeler AW
Regulatory Toxicology and Pharmacology 2002; 35: 398-413

Click here to read the abstract

A Review of L-tyrosine Confirming its Safe Human Use as an Adjuvant

Baldrick P, Richardson D, Wheeler AW.
Journal of Applied Toxicology 2002; 22: 333-344

Click here to read the abstract

Short-term immunotherapy: results of a PMS study

Drachenberg KJ, Proell S, Urban E.
Allergologie 2002; 25: suppl. 2, 8-14 (text in German)

Click here to read the abstract

Short-term immunotherapy with tree pollen allergoids and the adjuvant monophosphoryl lipid A- results from a multi-centre, placebo-controlled, randomized, double-blind study

Drachenberg KJ, Heinzkill M, Urban E.
Allergologie 2002; 25(9): 466-474 (in German)

Click here to read the abstract

Immunophenotypic characterization of peripheral B cells during short-term immunotherapy with tree pollen allergoid and the immunoadjuvant monophosphoryl lipid A.

Roever AC, Reimann S, Zuberbier T, Worm M. J Invest
Allergol Clin Immunol 2002; 12(4): 227-23

Click here to read the abstract

A Th1-inducing adjuvant, MPL®, enhances antibody profiles in experimental animals suggesting it has the potential to improve the efficancy of allergy vaccines.

Wheeler AW, Marshall JS, Ulrich JT
International Archives of Allergy & Immunology 2001; 126: 135-139

Click here to read the abstract

Immunological adjuvants in allergy vaccines: past, present and future.

Wheeler AW, Woroniecki SR.
Allergology International 2001; 50: 295-301

Click here to read the abstract

A well-tolerated grass pollen specific allergy vaccine containing a novel adjuvant, monophosphoryl lipid A (MPL®), reduces allergic symptoms after only four preseasonal injections.

Drachenberg KJ, Wheeler AW, Stuebner P, Horak F.
Allergy 2001; 56: 498-505.

Click here to read the abstract

Standardisation of a glutaraldehyde-modified allergen tyrosine adsorbed vaccine using an assay system with a europium label.

Newland BJ, Lees BG, Woroniecki SR.
International Review of Allergology & Clinical Immunology 2001; 7(3): 95-101

Click here to read the abstract

Standardisation of glutaraldehyde-modified tyrosine-adsorbed tree pollen vaccines containing the Th1-inducing adjuvant, monophosphoryl lipid A (MPL®)

Hopkins M, Lees BG, Richardson DG, Woroniecki SR, Wheeler AW.
Allergologia et Immunopathologia 2001; 29(6): 245-254

Click here to read the abstract

Sublingual immunotherapy - results from a multi-centre, randomised, double-blind, placebo-controlled study with a standardised birch and grass/rye pollen extract. (In German)

Drachenberg KJ, Pfeiffer P, Urban E.
Allergologie 2001; 24(11): 525-534

Click here to read the abstract